Company Description
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally.
It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines.
The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema.
Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer.
Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies.
It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab.
The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
| Country | France |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 86,088 |
| CEO | Paul Hudson |
Contact Details
Address: 46 Avenue De La Grande Armee Paris, I0 75017 France | |
| Phone | 33153774400 |
| Website | sanofi.com |
Stock Details
| Ticker Symbol | SNY |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001121404 |
| CUSIP Number | 80105N105 |
| ISIN Number | US80105N1054 |
| Employer ID | 13-3529324 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Paul Hudson | Chief Executive Officer and Director |
| François-Xavier Roger | Executive Vice President and Chief Financial Officer |
| Madeleine Roach | Executive Vice President and Head of Business Operations |
| Laurent Gilhodes | Principal Accounting Officer and Vice President of Corporate Accounting |
| Dr. Josephine Fubara | Chief Science Officer of Consumer Health Care |
| Eva Schaefer-Jansen | Head of Investor Relations |
| Dante Beccaria | Global Compliance Officer and Vice President |
| Roy Papatheodorou | Executive Vice President and General Counsel |
| Josep Catlla | Head of Communications |
| Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 4, 2024 | F-3ASR | Filing |
| Apr 4, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 20, 2024 | 6-K | Report of foreign issuer |
| Mar 15, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 27, 2024 | 6-K | Report of foreign issuer |
| Feb 23, 2024 | IRANNOTICE | Notice of disclosure filed pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 |
| Feb 23, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Feb 15, 2024 | 6-K | Report of foreign issuer |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Feb 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |